Objectives Intrathecal drug delivery systems (IDDS) are an important method of pain control
for patients with refractory oncologic pain. Local anesthetics such as bupivacaine have been …

Objective. This article presents an overview of the use of intrathecal bupivacaine (with and
without opioid), focusing on laboratory data and clinical use for chronic pain. Some …

Background Intrathecal drug delivery is widely used for intractable cancer pain treatment. A
combination of drugs with morphine and bupivacaine is recommended in first line therapy. In …

Background Combining neuraxial opioids and local anesthetics in acute pain results in
improved duration of analgesia and reduced dosages and adverse effects. Although …

Background context: Bupivacaine is a local anesthetic agent of the amide class. This drug
has been used in many clinical situations including intrathecal infusion. The literature …

Adequate pain relief in patients with far advanced cancer sometimes requires intrathecal (IT)
administration of a combination of opioids and local anesthetics. Tumor progression as well …

Objective. Intrathecal opioid/local anesthetic mixtures are a popular alternative in
contemporary treatment of chronic nonmalignant pain. Unfortunately, its use is based solely …

Objective. To evaluate the stability and tolerability of high concentrations of bupivacaine-
opioid solutions when used by intrathecal infusion. Design. Prospective, open label, pilot …

Objective The only agent approved by the US Food and Drug Administration for chronic
intrathecal infusion for the treatment of chronic pain is morphine sulfate. In patients who do …

Objective. To demonstrate the efficacy and safety of the addition of bupivacaine in restoring
pain control and improving quality of life and activity level in patients with chronic …